2025
779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk
SKLEPINSKI S, HERRIN J, SINDHU SWARNA K, NEUMILLER J, GALINDO R, UMPIERREZ G, ROSS J, DENG Y, POLLEY E, MARON B, MCCOY R. 779-P: Cardiovascular Outcomes Associated with Dulaglutide, Exenatide, Liraglutide, and Semaglutide in Adults with Type 2 Diabetes at Moderate Cardiovascular Risk. Diabetes 2025, 74 DOI: 10.2337/db25-779-p.Peer-Reviewed Original ResearchModerate CVD riskCVD riskType 2 diabetesCardiovascular diseaseAssociated with lower hazardRisk of cardiovascular outcomesCardiovascular disease outcomesCox proportional hazards modelsCardiovascular outcomesGlucagon-like peptide-1 receptor agonistsModerate cardiovascular riskCardiovascular risk reductionDigestive and Kidney DiseasesPeptide-1 receptor agonistsPropensity score inverse probabilityProportional hazards modelHazard of deathDepartment visitsNational Institute of DiabetesHazard of MACETrial emulationMedicare AdvantageMedicare plansComparative riskHazards modelCARDIOVASCULAR OUTCOMES IN NEW USERS OF ONCE-WEEKLY GLP-1 RECEPTOR AGONISTS VS OTHER GLUCOSE-LOWERING THERAPIES AMONG MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
De Havenon A, Tan X, Noshad S, Harton J, Liang Y, Xie L, Noone J, Blaha M. CARDIOVASCULAR OUTCOMES IN NEW USERS OF ONCE-WEEKLY GLP-1 RECEPTOR AGONISTS VS OTHER GLUCOSE-LOWERING THERAPIES AMONG MEDICARE BENEFICIARIES WITH TYPE 2 DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE. Journal Of The American College Of Cardiology 2025, 85: 416. DOI: 10.1016/s0735-1097(25)00900-3.Peer-Reviewed Original ResearchOral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial
Marx N, Deanfield J, Mann J, Arechavaleta R, Bain S, Bajaj H, Tanggaard K, Birkenfeld A, Buse J, Davicevic-Elez Z, Desouza C, Emerson S, Engelmann M, Hovingh G, Inzucchi S, Jhund P, Mulvagh S, Pop-Busui R, Poulter N, Rasmussen S, Tu S, McGuire D, Group O. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation 2025, 151: 1639-1650. PMID: 40156843, PMCID: PMC12144549, DOI: 10.1161/circulationaha.125.074545.Peer-Reviewed Original ResearchConceptsOral semaglutideType 2 diabetesAdverse cardiovascular eventsCardiovascular eventsCardiovascular outcomesAdverse cardiovascular events outcomeEffects of oral semaglutidePrimary outcomeMajor adverse cardiovascular events outcomeAdverse event profilePrimary outcome eventNonfatal myocardial infarctionChronic kidney diseaseAtherosclerotic cardiovascular diseaseCardiovascular event outcomesSGLT2i treatmentSGLT2i useReceptor agonistsAdverse eventsPrespecified analysesFollow-upCardiovascular deathRandomized trialsSemaglutideNonfatal strokeTemporal changes in PET myocardial flow reserve: Implications for cardiovascular outcomes
Nikolakopoulos I, Csecs I, Liu Y, Sinusas A, Miller E, Feher A. Temporal changes in PET myocardial flow reserve: Implications for cardiovascular outcomes. Journal Of Nuclear Cardiology 2025, 48: 102194. PMID: 40139484, DOI: 10.1016/j.nuclcard.2025.102194.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsMyocardial perfusion imagingEvaluation of coronary artery diseasePositron emission tomographyClinical risk factorsMyocardial flow reserveCoronary artery diseasePositron emission tomography myocardial perfusion imagingRates of major-adverse cardiovascular eventsCardiovascular outcomesArtery diseaseFlow reserveMedian follow-up timeRisk factorsLong-term major adverse cardiovascular eventsHistory of heart transplantationC-statisticMedian interval timeKaplan-Meier methodFollow-up timeAdverse cardiovascular eventsChest painTransplant vasculopathyMyocardial blood flowHeart transplantationOptimizing Psychological Health Across the Perinatal Period: An Update on Maternal Cardiovascular Health: A Scientific Statement From the American Heart Association
Sharma G, Gaffey A, Hameed A, Kasparian N, Mauricio R, Marsh E, Beck D, Skowronski J, Wolfe D, Levine G, Research T. Optimizing Psychological Health Across the Perinatal Period: An Update on Maternal Cardiovascular Health: A Scientific Statement From the American Heart Association. Journal Of The American Heart Association 2025, 14: e041369. PMID: 39996493, PMCID: PMC12132617, DOI: 10.1161/jaha.125.041369.Peer-Reviewed Original ResearchConceptsMaternal cardiovascular healthPsychological healthCardiovascular healthAmerican Heart AssociationPerinatal periodCare delivery modelsMaternal psychological healthScientific statementPsychological health carePostpartum follow-upHeart AssociationPsychological health conditionsAssociated with adverse pregnancy outcomesCardiovascular outcomesMaternal mortalityAdverse pregnancy outcomesHealth careDelivery modelsHealth conditionsLong-term cardiovascular outcomesHealthStakeholder partnersOffspring neurodevelopmentPregnancy outcomesCareIndividualized Net Benefit of Intensive Blood Pressure Lowering Among Community‐Dwelling Older Adults in SPRINT
Jamshidian M, Scherzer R, Estrella M, Kravitz R, Boxer R, Tancredi D, Berry J, de Lemos J, Ginsberg C, Ix J, Shlipak M, Ascher S. Individualized Net Benefit of Intensive Blood Pressure Lowering Among Community‐Dwelling Older Adults in SPRINT. Journal Of The American Geriatrics Society 2025, 73: 1441-1453. PMID: 39967308, PMCID: PMC12100678, DOI: 10.1111/jgs.19395.Peer-Reviewed Original ResearchSystolic Blood Pressure Intervention TrialCommunity-dwelling older adultsIntensive blood pressureSystolic BP targetOlder adultsBlood pressureIndividual net benefitsIntensive BPBP targetsAdvanced ageSystolic Blood Pressure Intervention Trial participantsBenefits of BPOptimal blood pressureTreatment-related harmsCategories of ageAdverse eventsPositive net benefitsFrailty statusCardiovascular outcomesCognitive outcomesIntervention trialsCox modelRisk differenceSystolicPolypharmacyA Bayesian Interpretation of CABANA and Other Randomized Controlled Trials for Catheter Ablation in Patients With Atrial Fibrillation
Nogueira A, Felix N, Kalil F, Tramujas L, Godoi A, Miyawaki I, Bellavia A, Moura F, Cardoso R, d'Avila A, Fernandes G. A Bayesian Interpretation of CABANA and Other Randomized Controlled Trials for Catheter Ablation in Patients With Atrial Fibrillation. Journal Of Cardiovascular Electrophysiology 2025, 36: 617-624. PMID: 39834105, DOI: 10.1111/jce.16552.Peer-Reviewed Original ResearchConceptsBayesian analysisTreatment effect distributionAdverse cardiovascular outcomesAll-cause mortalityCardiovascular outcomesRandomized controlled trialsFrequentist estimatorsCatheter ablationMedical therapyAtrial fibrillationBayesian interpretationImpact of catheter ablationControlled trialsAnalysis of randomized controlled trialsProbability distributionAtrial fibrillation patientsReduce adverse cardiovascular outcomesImpact of ablationEffective distributionRandom-effects modelBayes' theoremTrial-level dataProbabilistic understandingSurvival outcomesFibrillation patientsSkeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes
do A H Souza A, Troschel A, Marquardt J, Hadžić I, Foldyna B, Moura F, Hainer J, Divakaran S, Blankstein R, Dorbala S, Di Carli M, Aerts H, Lu M, Fintelmann F, Taqueti V. Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomes. European Heart Journal 2025, 46: 1112-1123. PMID: 39827905, DOI: 10.1093/eurheartj/ehae827.Peer-Reviewed Original ResearchCoronary microvascular dysfunctionBody mass indexCoronary flow reserveIntermuscular adipose tissueSubcutaneous adipose tissueHeart failureFat infiltrationMarker of coronary microvascular dysfunctionPreserved left ventricular ejection fractionCardiovascular outcomesAssociated with coronary microvascular dysfunctionHigher IMATIncreased IMATPresence of coronary microvascular dysfunctionSkeletal muscleFlow reserveIncreased risk of MACEMyocardial infarctionStress positron emission tomographyAssociated with increased MACERisk of heart failureLow coronary flow reserveThoracic vertebra levelVentricular ejection fractionIntermuscular adipose tissue areaMortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study
Njei B, Mezzacappa C, John B, Serper M, Kaplan D, Taddei T, Mahmud N. Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Digestive Diseases And Sciences 2025, 70: 802-813. PMID: 39779587, PMCID: PMC11839701, DOI: 10.1007/s10620-024-08764-4.Peer-Reviewed Original ResearchConceptsNon-lean individualsAll-cause mortalityMajor adverse cardiovascular eventsIncreased risk of all-cause mortalityRisk of all-cause mortalityVeterans Health AdministrationRisk of hepatic decompensationPrevalence of diabetesRisk of cardiovascular mortalityHepatic decompensationHigher mortality riskCardiovascular-related mortalityCox proportional hazards modelsCohort study of patientsCardiovascular outcomesIncident major adverse cardiovascular eventsRetrospective cohort study of patientsProportional hazards modelNon-HispanicRetrospective cohort studyCompeting risk regressionHealth AdministrationMultivariate Cox proportional hazards modelLean individualsAssessed associations
2024
Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis
Rassi A, Grimshaw A, Sarwal A, Sah R, Shah S, Agudelo Higuita N, Rassi F, Corbisiero M, Kyllo H, Stellern J, Kaplan S, Marcos L, Ramírez-García E, Casapia M, Hotez P, Bottazzi M, Patel S, Franco-Paredes C, Marin-Neto J, Henao-Martínez A. Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysis. EClinicalMedicine 2024, 79: 102972. PMID: 39810938, PMCID: PMC11732499, DOI: 10.1016/j.eclinm.2024.102972.Peer-Reviewed Original ResearchChronic Chagas diseaseMethodological quality of studiesCardiovascular deathQuality of studiesDisease progressionQuality of evidenceVirtual Health Library databasesRisk of bias scaleCardiovascular outcomesRandom-effects modelPooled risk ratioMeta-analysis of studiesMethodological qualityWeb of Science Core CollectionAntitrypanosomal therapyRandomized controlled studyManagement of Chagas diseaseOvid MEDLINESystematic reviewInclusion criteriaMeta-analysesRisk ratioScience Core CollectionPrimary outcomeOvid EmbaseDemographic diversity in platelet function and response to antiplatelet therapy
Jain K, Tyagi T, Gu S, Faustino E, Hwa J. Demographic diversity in platelet function and response to antiplatelet therapy. Trends In Pharmacological Sciences 2024, 46: 78-93. PMID: 39672782, PMCID: PMC11710996, DOI: 10.1016/j.tips.2024.11.005.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsResponse to antiplatelet therapyCardiovascular diseaseAntiplatelet therapyPlatelet biologyPathological platelet activationCardiovascular disease riskNon-genetic factorsPopulation-based differencesAntiplatelet strategiesPlatelet functionCardiovascular outcomesDiverse rolesPlatelet activationTherapeutic approachesTherapyPlateletBiologyThe Association Between Rheumatic Disease Therapies and Cardiovascular Outcomes in People with HIV—A Retrospective Cohort Study
Titanji B, Nagatomi S, Gallini J, Cui X, Hanberg J, Hsieh E, Marconi V. The Association Between Rheumatic Disease Therapies and Cardiovascular Outcomes in People with HIV—A Retrospective Cohort Study. Journal Of Clinical Medicine 2024, 13: 6209. PMID: 39458159, PMCID: PMC11508247, DOI: 10.3390/jcm13206209.Peer-Reviewed Original ResearchRisk of CVD eventsElectronic health recordsCardiovascular disease eventsCVD eventsRetrospective cohort studyCardiovascular diseaseCohort studyIncidence of CVD eventsIncreased risk of CVD eventsRheumatic diseasesCardiovascular disease outcomesCardiovascular disease riskRisk of cardiovascular diseaseHealth recordsAssociated with increased CVD eventsGeneral populationPrimary outcomeDisease therapyAtlanta VAMCIncreased riskHIV infectionExacerbated inflammationCardiovascular outcomesPatient populationHIVSemaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
Deanfield J, Verma S, Scirica B, Kahn S, Emerson S, Ryan D, Lingvay I, Colhoun H, Plutzky J, Kosiborod M, Hovingh G, Hardt-Lindberg S, Frenkel O, Weeke P, Rasmussen S, Goudev A, Lang C, Urina-Triana M, Pietilä M, Lincoff A, Investigators S, Abe M, Abhaichand R, Abhayaratna W, Abhyankar A, Abidin I, Assi H, Mendoza J, Adas M, Agaiby J, Agarwal D, Agha M, Ahmed A, Ahtiainen P, Aigner E, Ajay N, Ali N, Al-Karadsheh A, Allison R, Allison D, Alpenidze D, Altuntas Y, Al-Zoebi A, Ambuj R, Amerena J, Anderson R, Ando T, Andrews R, Antonova E, Appel K, Arantes F, Araz M, Arbel Y, León J, Argyrakopoulou G, Ariani M, Mendoza M, Arif A, Arneja J, Aroda V, Aronne L, Arstall M, Asamoah N, Asanin M, Audish H, Avram R, Badat A, Badiu C, Bakdash W, Bakiner O, Bandezi V, Bang L, Bansal S, Baranyai M, Barbarash O, Barber M, Barnum O, Rochette G, Bashkin A, Baum S, Bays H, Ruiz A, Beckowski M, Beerachee Y, Bellary S, Belousova L, Berk M, Bernstein M, Berra C, Beshay I, Bhagwat A, Bhan A, Biggs W, Billings L, Bitar F, Block B, Bo S, Bogdanski P, Bolshakova O, Boshchenko A, Bosworth H, Lopez R, Bôttcher M, Bourgeois R, Brautigam D, Breton C, Broadley A, Brockmyre A, Brodie S, Bucci M, Budincevic H, Budoff M, Buffman B, Buljubasic N, Buranapin S, Burgess L, Burguera B, Buriakovska O, Buscemi S, Busch R, Buse J, Buynak R, Byrne M, Caceaune E, Bonfanti A, Calinescu C, Call R, Varzic S, Cannon K, Capehorn M, Cariou B, Carr J, Carrillo-Jimenez R, Casas M, Castro A, Celik A, Cercato C, Cermak O, Y J, Chacon C, Chaicha-Brom T, Chandra S, Chettibi M, Chevts J, Christopher J, Chrustowski W, Cif A, Clark R, Clark W, Clifford P, Coetzee K, Cogni G, Colao A, Colquhoun D, Concha M, Condit J, Constance C, Constantin C, Constantinescu S, Corbett C, Cornett G, Correia M, Cortinovis F, Cosma D, Creely S, Cross D, Curtis B, Czochra W, Daboul N, Dagdelen S, D'agostino R, Dang C, Datta S, Davuluri A, Dawood S, De Jong D, De La Cuesta C, De Los Rios Ibarra M, De Pablo C, De Pauw M, Dela Llana A, Delibasic M, Delic-Brkljacic D, Demicheli T, Denger R, Desai D, Desai P, Desouza C, Dicker D, Djenic N, Dobson S, Doi M, Doran J, Dorman R, Dotta F, Dukes C, Duronto E, Durst R, Dvoryashina I, Ebrahim I, Eggebrecht H, Egstrup K, Ekinci E, Eliasson B, Eliasson K, Enache G, Enculescu D, English P, Ermakova P, Ershova O, Ezaki H, Ezhov M, Farias E, Farias J, Farsky P, Ferreira D, Filteau P, Finneran M, Folkens E, Fonseca A, Fonseca L, Fordan S, Fourie N, França S, Franco D, Franek E, Friedman K, Frittitta L, Froer M, Fuckar K, Fujii K, Fujita R, Fukushima Y, Fulat M, Fulwani M, Gajos G, Galyavich A, Gambill M, Gandotra D, Winston G, Hernandez P, Reza R, Garg N, Garg S, Garvey W, Garza J, Gatta-Cherifi B, Gelev V, Geller S, Geohas J, Georgiev B, Ghazi A, Gilbert M, Gilinskaya O, Gislason G, Yavuz D, Albarrán O, Gordeev I, Gorton S, Goudev A, Valderhaug T, Groenemeijer B, Gul I, Gullestad L, Gurieva I, Guseva G, Hagenow A, Haluzik M, Halvorsen S, Hammoudi N, Hanaoka K, Hancu N, Hanusch U, Harris K, Harris B, Hartleib M, Hartman A, Hata Y, Heimer B, Herman L, Herzog W, Hewitt E, Heymer P, Hiremath S, Hjelmesaeth J, Høgalmen R, Høivik H, Holmer H, Horoshko O, Houser P, Hove J, Hsieh I, Hulot J, Hussein Z, Ilashchuk T, Ilveskoski E, Ipatko I, Iranmanesh A, Isawa T, Issa M, Iteld B, Iwasawa T, Jabbar D, Jackson R, Jackson-Voyzey E, Jacob S, Jaffrani N, Jardula M, Jastreboff A, Jensen S, Jerkins T, Jimenez-Ramos S, Singh S, Johnson W, Joyce J, Jozefowska M, Jugnundan P, Jungmair W, Jurowiecki J, Kadokami T, Kahali D, Kahrmann G, Kaiser S, Kalmucki P, Kanadasi M, Kandath D, Kania G, Kannan J, Kapp C, Karczmarczyk A, Kartalis A, Kaser S, Kasim S, Kastelic R, Kato T, Katova T, Kaul U, Kautzky-Willer A, Kawanishi M, Kayikcioglu M, Kazakova E, Keeling P, Kempe H, Kereiakes D, Kerneis M, Keski-Opas T, Khadra S, Khaisheva L, Kharakhulakh M, Khlevchuk T, Khoo J, Kiatchoosakun S, Kinoshita N, Kinoshita M, Kitamura R, Kiyosue A, Klavina I, Klein E, Klimsa Z, Klonoff D, Klug E, Kobalava Z, Kodera S, Koga T, Kokkinos A, Koleckar P, Könyves L, Koren M, Kormann A, Kostner K, Kreutzmann K, Krishinan S, Krishnasamy S, Krivosheeva I, Kruljac I, Kubicki T, Kuchar L, Kujawiak M, Kunishige H, Kurtinecz M, Lisboa H, Kushnir M, Kyyak Y, Lace A, Lakka T, Lalic N, Lalic K, Lambadiari V, Lanaras L, Lang C, Langlois M, Lash J, Latkovskis G, Lau D, Soto J, Le Roux C, Ledesma G, Lee L, Lee T, Lee K, Lehrke M, Leite S, Leksycka A, Lenzmeier T, Leonetti F, Leonidova V, Lepor N, Leung M, Levchenko O, Levins P, Levy L, Lewis M, Liberopoulos E, Liberty I, Lindholm C, Lingvay I, Linhart A, Liu M, Liu J, Lofton H, Logemann T, Lombaard J, Lombard L, Lorraine R, Lovell C, Ludvik B, Lukaszewicz M, Lupkovics G, Lupovitch S, Lupu S, Lynch M, Lysak Z, Lysenko T, Maeda H, Maeda I, Mæng M, Mahajan A, Maher V, Maia L, Makotoko E, Malavazos A, Malecha J, Malicherova E, Manita M, Mannucci E, Mareev V, Marin L, Markova T, Marso S, Martens F, Martinez C, Cano C, Martins C, Comas L, Matsumoto T, Mcdonald K, Mcgowan B, Mcgrew F, Mclean B, Mcpherson D, Torres J, Meyers P, Meyhöfer S, Raya P, Milanova M, Milicic D, Miller G, Mills R, Mîndrescu N, Mingrone G, Minkova D, Mirani M, Miras A, Mistodie C, Mitomo S, Mittal S, Miyake T, Miyamoto N, Molony D, Monteiro P, Mooe T, Moosa N, Portillo C, Villegas E, Morawski E, Morbey C, Morin R, Morisaki K, Morosanu M, Mosenzon O, Mostovoy Y, Munir I, Muratori F, Murray R, Murthy A, Myint M, Myshanych G, Nafornita V, Nagano T, Nair S, Nakhle S, Natsuaki M, Nayak B, Nibouche D, Nicholls S, Nicolau J, Nicolescu G, Nierop P, Niskanen L, Ntaios G, Nygård O, Oaks J, Obrezan A, O'donnell P, Oguri M, Oguzhan A, Oh F, Ohsugi M, Okada Y, Okayama H, Onaca A, Onaka H, Oneil P, Ong T, Ong S, Ono Y, Opsahl P, Ostrowska L, Oviedo A, Ozdogan O, Ozpelit E, Pagkalos E, Pagotto U, Páll D, Pandey A, Parkhomenko O, Parvathareddy K, Patel M, Patsilinakos S, Paul N, Pedersen S, Pereira I, Pereira E, Terns P, Perez-Vargas E, Pergaeva Y, Perkelvald A, Peskov A, Peter J, Peters K, Petit C, Petrov I, Philis-Tsimikas A, Pietilä M, Pinto F, Piros A, Piyayotai D, Platonov D, Poirier P, Pop L, Popa B, Pop-Busui R, Poremba J, Porto A, Postadzhiyan A, Pothineni R, Potu R, Powell T, Prafulla K, Prager R, Prakova-Teneva Z, Pratley R, Price H, Pulka G, Pullman J, Punt Z, Purighalla R, Purnell P, Qureshi M, Rabasa-Lhoret R, Raikhel M, Rancane G, Randeva H, Rasouli N, Pintilei D, Reyes C, Rezgale I, Rice E, Riley T, Risser J, Ristic A, Fernández M, Robbins D, Robitaille Y, Rodbard H, Plazas J, Römer T, Rosen G, Rosman A, Rossi P, Rudenko L, Ruffin O, Ruhani A, Runev N, Ruyatkin D, Ruzic A, Ryabov V, Rydén L, Saggar S, Sakamoto T, Salter T, Samal A, Samoilova Y, Sanabria H, Sancak S, Sangrigoli R, Sansanayudh N, Santini F, Saraiva J, Sardinov R, Sargeant W, Sari R, Sathananthan A, Sathyapalan T, Sato A, Sauter J, Sbraccia P, Schaap J, Schaum T, Schiele F, Scott J, Lieberman G, Segner A, Senior R, Sergeeva-Kondrachenko M, Serota H, Serusclat P, Sethi R, Shah M, Shah N, Shalaev S, Sharma R, Sharma S, Shaydyuk O, Shea H, Shechter M, Shehadeh N, Shirazi M, Shlesinger Y, Shneker A, Shutemova E, Siasos G, Siddiqui I, Sidey J, Sigal F, Sime I, Singh N, Siraj E, Sivalingam K, Skoczylas G, Smith S, Smolenskaya O, Snyder B, Sofer Y, Sofley C, Solano R, Sonmez Y, Sorokin M, González A, Sotolongo C, Soufer J, Selcukbiricik O, Spaic T, Spriggs D, Sreenan S, Stahl H, Stamatelopoulos K, Stanislavchuk M, Stankovic G, Stasek J, Steg G, Steindorf J, Stephan D, Stewart J, Still C, St-Maurice F, Stogowska-Nikiciuk B, Stoker J, Stokic E, Strzelecka A, Sturm K, Sueyoshi A, Sugiura T, Sultan S, Suplotova L, Suwanagool A, Suwanwalaikorn S, Sveklina T, Swanson N, Swart H, Swenson B, Szyprowska E, Tait G, Takács R, Takeuchi Y, Tamirisa A, Tanaka H, Tatovic D, Tellier G, Teragawa H, Teterovska D, Thomas N, Thuan J, Tinahones F, Tisheva-Gospodinova S, Toarba C, Todoriuk L, Tokmakova M, Tonstad S, Toplak H, Tran H, Tripathy D, Trusau A, Tsabedze N, Tsougos E, Tsoukas G, Tuccinardi D, Tuna M, Turatti L, Tziomalos K, Udommongkol C, Ueda O, Ukkola O, Unubol M, Urbach D, Triana M, Usdan L, Vaidya B, Vale N, Vallieres G, Van Beek A, Van De Borne P, Van Der Walt E, Van Der Zwaan C, Van Nieuwenhuizen E, Van Zyl L, Vanduynhoven P, Varghese K, Vasileva S, Vassilev D, Vathesatogkit, Velychko V, Vercammen C, Verges B, Verma S, Verwerft J, Vesela A, Veselovskaya N, Vettor R, Veze I, Vijan V, Vijayaraghavan R, Villarino A, Vincent R, Vinogradova O, Vishlitzky V, Vlad A, Vladu I, Vo A, Von Engelhardt C, Von Münchhausen C, Vorobyeva O, Vossenberg T, Vrolix M, Vukicevic M, Vyshnyvetskyy I, Wadvalla S, Wagner J, Wakeling J, Wallace J, Mohamed W, Wander G, Ward K, Warren M, Watanabe A, Weber B, Weintraub H, Weisnagel J, Welker J, Wendisch U, Wenocur H, Wierum C, Wilding J, William M, Wilson P, Wilson J, Wong Y, Wongcharoen W, Wozniak I, Wu C, Wyatt N, Wynne A, Yamaguchi H, Yamasaki M, Yazici D, Yeh H, Yotov Y, Yuan Q, Zacher J, Zagrebelnaya O, Zaidman C, Zalevskaya A, Zarich S, Zatelli M, Zeller H, Zhdanova E, Zornitzki T, Zrazhevskiy K, Zykov M, Lincoff A, Ryan D, Colhoun H, Deanfield J, Emerson S, Kahn S, Kushner R, Plutzky J, Brown-Frandsen K, Hovingh G, Hardt-Lindberg S, Tornøe C. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. The Lancet 2024, 404: 773-786. PMID: 39181597, DOI: 10.1016/s0140-6736(24)01498-3.Peer-Reviewed Original ResearchConceptsReduced ejection fractionOnce-weekly subcutaneous semaglutideHistory of heart failureEjection fractionHeart failureHeart failure subtypesAtherosclerotic cardiovascular diseaseSubcutaneous semaglutideBaseline characteristicsCardiovascular diseaseEffects of once-weekly subcutaneous semaglutideNew York Heart Association statusCardiovascular outcomesInteractive web response systemIncidence of clinical eventsGLP-1 receptor agonistsHeart failure endpointsSafety of semaglutideSubtypes of heart failureWeb response systemClinical heart failureEffect of semaglutideDouble-blind mannerSerious adverse eventsPhase 3 trialAssociation of door-to-balloon time and one-year outcomes in hospital survivors of ST-elevation myocardial infarction
Sawano M, Kohsaka S, Murugiah K, Ishii H, Yamaji K, Takahashi J, Ozaki K, Amano T, Kozuma K. Association of door-to-balloon time and one-year outcomes in hospital survivors of ST-elevation myocardial infarction. Journal Of Cardiology 2024, 85: 98-99. PMID: 38964710, DOI: 10.1016/j.jjcc.2024.06.009.Peer-Reviewed Original ResearchDoor-to-balloon timeST-elevation myocardial infarctionAdjusted hazard ratiosSurvivors of ST-elevation myocardial infarctionMyocardial infarctionPatients aged <Specific patient subgroupsAdverse cardiovascular eventsOne-year outcomesAcute coronary eventsRevascularization historyMACE riskCardiogenic shockCoronary revascularizationOutcomes RegistryCardiovascular eventsHospital survivorsPatient subgroupsCardiac arrestSubgroup analysisCardiovascular outcomesHazard ratioHigher comorbiditiesCoronary eventsPrimary preventionTemporal change in PET myocardial flow reserve is predictive of cardiovascular outcomes
Nikolakopoulos I, Liu Y, Sinusas A, Miller E, Feher A. Temporal change in PET myocardial flow reserve is predictive of cardiovascular outcomes. European Heart Journal - Cardiovascular Imaging 2024, 25: jeae142.099. DOI: 10.1093/ehjci/jeae142.099.Peer-Reviewed Original ResearchPositron emission tomographyMyocardial flow reserveCoronary artery diseaseCardiovascular outcomesArtery diseaseFlow reserveEvaluation of coronary artery diseaseHistory of heart transplantationMedian interval timeKaplan-Meier methodPredictive of cardiovascular outcomesLong-term outcomesPerioperative risk stratificationCoronary bloodChest painHeart transplantationRisk stratificationSerial examsCox regressionMyocardial infarctionInterquartile rangeC-statisticEmission tomographyPatientsContinuous variablesInterleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor
Brösecke F, Pfau A, Ermer T, Dein Terra Mota Ribeiro A, Rubenbauer L, Rao V, Burlein S, Genser B, Reichel M, Aronson P, Coca S, Knauf F. Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor. Scientific Reports 2024, 14: 11323. PMID: 38760468, PMCID: PMC11101424, DOI: 10.1038/s41598-024-61808-7.Peer-Reviewed Original ResearchConceptsIL-16 levelsIL-16Dialysis patientsCardiovascular eventsConcentrations of IL-16Kidney failureUremic toxinsCardiovascular diseaseCompared to healthy individualsPlasma oxalate concentrationActivated immune cellsAssociated with cardiovascular diseaseIL-16 concentrationCytokine IL-16Cardiovascular risk factorsNo significant associationPlasma oxalateInflammatory markersImmune cellsCytokine concentrationsInterleukin-16US patientsCohort 1Cardiovascular outcomesHealthy individualsImpact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease
Wong R, Yang Z, Yeoh A, Do A, Ahmed A, Cheung R. Impact of HIV Infection on Liver and Cardiovascular Outcomes in Veterans With Metabolic Dysfunction-Associated Steatotic Liver Disease. The American Journal Of Gastroenterology 2024, 119: 1841-1848. PMID: 38477465, DOI: 10.14309/ajg.0000000000002760.Peer-Reviewed Original ResearchConceptsImpact of HIV infectionAntiretroviral therapyIncidence of cirrhosisAdverse cardiovascular eventsHIV infectionHepatocellular carcinomaAssociated with greater riskCardiovascular diseaseOverall survivalCardiovascular eventsLiver diseaseSteatotic liver diseaseConcurrent HIV infectionDecreased overall survivalRisk of cirrhosisRisk of liverGreater riskLiver disease progressionPropensity-matched cohortScore-matched cohortCardiovascular disease outcomesUS veteransCardiovascular outcomesDisease progressionPrimary outcomeASSOCIATIONS OF ULTRA LONG-TERM VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY SINCE CHILDHOOD WITH VASCULAR AGING IN MIDLIFE: A 30-YEAR PROSPECTIVE COHORT STUDY
Wang Y, -Ma A, Zhao P, Chu C, Du M, Wang D, Jia H, Hu G, Ma Q, Yan Y, Chang J, Delles C, Chen F, Mu J. ASSOCIATIONS OF ULTRA LONG-TERM VISIT-TO-VISIT BLOOD PRESSURE VARIABILITY SINCE CHILDHOOD WITH VASCULAR AGING IN MIDLIFE: A 30-YEAR PROSPECTIVE COHORT STUDY. Journal Of Hypertension 2024, 42: e11. DOI: 10.1097/01.hjh.0001019424.08488.b4.Peer-Reviewed Original ResearchLong-term BP variabilityPresence of carotid plaqueBlood pressureAverage real variabilityArterial stiffnessBP variabilityCarotid hypertrophyMean BPCarotid plaquesSubpopulation treatment effect pattern plot methodologyVascular agingFunctional arterial propertiesYears of follow-upAssociated with arterial stiffnessPredictor of cardiovascular diseaseHigher BP variabilityPredictor of cardiovascular outcomesLong-term blood pressureAssociated with riskExposure to BPParticipants aged 6Clinical characteristicsFollow-upCohort studyCardiovascular outcomesEffectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk
McCoy R, Herrin J, Swarna K, Deng Y, Kent D, Ross J, Umpierrez G, Galindo R, Crown W, Borah B, Montori V, Brito J, Neumiller J, Mickelson M, Polley E. Effectiveness of glucose-lowering medications on cardiovascular outcomes in patients with type 2 diabetes at moderate cardiovascular risk. Nature Cardiovascular Research 2024, 3: 431-440. PMID: 38846711, PMCID: PMC11156225, DOI: 10.1038/s44161-024-00453-9.Peer-Reviewed Original ResearchAdverse cardiovascular eventsGlucose-lowering medicationsType 2 diabetesCardiovascular diseaseGLP-1RACardiovascular eventsGlucagon-like peptide-1 receptor agonistsSodium-glucose cotransporter 2 inhibitorsPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsPeptidase-4 inhibitorsRetrospective cohort studyCardiovascular disease risk reductionGlucose-lowering agentsModerate cardiovascular riskCardiovascular risk reductionReceptor agonistsEffects of glucose-lowering medicationsRisk reductionCardiovascular riskCohort studyCardiovascular outcomesHigh riskBaseline riskModerate riskCardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
Green J, Everett B, Ghosh A, Younes N, Krause-Steinrauf H, Barzilay J, Desouza C, Inzucchi S, Pokharel Y, Schade D, Scrymgeour A, Tan M, Utzschneider K, Mudaliar S, Crandall J, McKee M, Behringer-Massera S, Brown-Friday J, Xhori E, Ballentine-Cargill K, Duran S, Estrella H, Gonzalez de la Torre S, Lukin J, Phillips L, Burgess E, Olson D, Rhee M, Wilson P, Raines T, Boers J, Costello J, Maher-Albertelli M, Mungara R, Savoye L, White C, Gullett C, Holloway L, Morehead F, Person S, Sibymon M, Tanukonda S, Adams C, Ross A, Balasubramanyam A, Gaba R, Gonzalez Hattery E, Ideozu A, Jimenez J, Montes G, Wright C, Hollander P, Roe E, Jackson A, Smiley A, Burt P, Estrada L, Chionh K, Ismail-Beigi F, Falck-Ytter C, Sayyed Kassem L, Sood A, Tiktin M, Kulow T, Newman C, Stancil K, Cramer B, Iacoboni J, Kononets M, Sanders C, Tucker L, Werner A, Maxwell A, McPhee G, Patel C, Colosimo L, Krol A, Goland R, Pring J, Alfano L, Kringas P, Hausheer C, Tejada J, Gumpel K, Kirpitch A, Schneier H, AbouAssi H, Chatterjee R, Feinglos M, English Jones J, Khan S, Kimpel J, Zimmer R, Furst M, Satterwhite B, Thacker C, Evans Kreider K, Mariash C, Mather K, Ismail H, Lteif A, Mullen M, Hamilton T, Patel N, Riera G, Jackson M, Pirics V, Aguillar D, Howard D, Hurt S, Bergenstal R, Carlson A, Martens T, Johnson M, Hill R, Hyatt J, Jensen C, Madden M, Martin D, Willis H, Konerza W, Yang S, Kleeberger K, Passi R, Fortmann S, Herson M, Mularski K, Glauber H, Prihoda J, Ash B, Carlson C, Ramey P, Schield E, Torgrimson-Ojerio B, Arnold K, Kauffman B, Panos E, Sahnow S, Bays K, Berame K, Cook J, Ghioni D, Gluth J, Schell K, Criscola J, Friason C, Jones S, Nazarov S, Rassouli N, Puttnam R, Ojoawo B, Nelson R, Curtis M, Hollis B, Sanders-Jones C, Stokes K, El-Haqq Z, Kolli A, Tran T, Wexler D, Larkin M, Meigs J, Chambers B, Dushkin A, Rocchio G, Yepes M, Steiner B, Dulin H, Cayford M, Chu K, DeManbey A, Hillard M, Martin K, Thangthaeng N, Gurry L, Kochis R, Raymond E, Ripley V, Stevens C, Park J, Aroda V, Ghazi A, Magee M, Ressing A, Loveland A, Hamm M, Hurtado M, Kuhn A, Leger J, Manandhar L, Mwicigi F, Sanchez O, Young T, Garg R, Lagari-Libhaber V, Florez H, Valencia W, Marks J, Casula S, Oropesa-Gonzalez L, Hue L, Cuadot A, Nieto-Martinez R, Riccio Veliz A, Gutt M, Kendal Y, Veciana B, Ahmann A, Aby-Daniel D, Joarder F, Morimoto V, Sprague C, Yamashita D, Cady N, Rivera-Eschright N, Kirchhoff P, Morales Gomez B, Adducci J, Goncharova A, Hox S, Petrovitch H, Matwichyna M, Jenkins V, Broadwater L, Ishii R, Bermudez N, Hsia D, Cefalu W, Greenway F, Waguespack C, King E, Fry G, Dragg A, Gildersleeve B, Arceneaux J, Haynes N, Thomassie A, Pavlionis M, Bourgeois B, Hazlett C, Henry R, Boeder S, Pettus J, Diaz E, Garcia-Acosta D, Maggs S, DeLue C, Stallings A, Castro E, Hernandez S, Krakoff J, Curtis J, Killean T, Khalid M, Joshevama E, Diaz E, Martin D, Tsingine K, Karshner T, Albu J, Pi-Sunyer F, Frances S, Maggio C, Ellis E, Bastawrose J, Gong X, Banerji M, August P, Lee M, Lorber D, Brown N, Josephson D, Thomas L, Tsovian M, Cherian A, Jacobson M, Mishko M, Kirkman M, Buse J, Diner J, Dostou J, Machineni S, Young L, Bergamo K, Goley A, Kerr J, Largay J, Guarda S, Cuffee J, Culmer D, Fraser R, Almeida H, Coffer S, Debnam E, Kiker L, Morton S, Josey K, Fuller G, Garvey W, Cherrington A, Dyer D, Lawson M, Griffith O, Agne A, McCullars S, Cohen R, Craig J, Rogge M, Burton K, Kersey K, Wilson C, Lipp S, Vonder Meulen M, Adkins C, Onadeko T, Rasouli N, Baker C, Schroeder E, Razzaghi M, Lyon C, Penaloza R, Underkofler C, Lorch R, Douglass S, Steiner S, Sivitz W, Cline E, Knosp L, McConnell J, Lowe T, Herman W, Pop-Busui R, Martin C, Waltje A, Katona A, Goodhall L, Eggleston R, Kuo S, Bojescu S, Bule S, Kessler N, LaSalle E, Whitley K, Seaquist E, Bantle A, Harindhanavudhi T, Kumar A, Redmon B, Bantle J, Coe M, Mech M, Taddese A, Lesne L, Smith S, Kuechenmeister L, Shivaswamy V, Burbach S, Rodriguez M, Seipel K, Alfred A, Morales A, Eggert J, Lord G, Taylor W, Tillson R, Adolphe A, Burge M, Duran-Valdez E, Martinez J, Bancroft A, Kunkel S, Ali Jamaleddin Ahmad F, Hernandez McGinnis D, Pucchetti B, Scripsick E, Zamorano A, DeFronzo R, Cersosimo E, Abdul-Ghani M, Triplitt C, Juarez D, Mullen M, Garza R, Verastiqui H, Wright K, Puckett C, Raskin P, Rhee C, Abraham S, Jordan L, Sao S, Morton L, Smith O, Osornio Walker L, Schnurr-Breen L, Ayala R, Kreymer R, Sturgess D, Kahn S, Alarcon-Casas Wright L, Boyko E, Tsai E, Trence D, Trikudanathan S, Fattaleh B, Montgomery B, Atkinson K, Kozedub A, Concepcion T, Moak C, Prikhodko N, Rhothisen S, Elasy T, Martin S, Shackelford L, Goidel R, Hinkle N, Lovell C, Myers J, Lipps Hogan J, McGill J, Salam M, Schweiger T, Kissel S, Recklein C, Clifton M, Tamborlane W, Camp A, Gulanski B, Pham K, Alguard M, Gatcomb P, Lessard K, Perez M, Iannone L, Magenheimer E, Montosa A, Cefalu W, Fradkin J, Burch H, Bremer A, Nathan D, Lachin J, Buse J, Kahn S, Larkin M, Tiktin M, Wexler D, Burch H, Bremer A, Lachin J, Bebu I, Butera N, Buys C, Fagan A, Gao Y, Gramzinski M, Hall S, Kazemi E, Legowski E, Liu H, Suratt C, Tripputi M, Arey A, Backman M, Bethepu J, Lund C, Mangat Dhaliwal P, McGee P, Mesimer E, Ngo L, Steffes M, Seegmiller J, Saenger A, Arends V, Gabrielson D, Conner T, Warren S, Day J, Huminik J, Soliman E, Zhang Z, Campbell C, Hu J, Keasler L, Hensley S, Li Y, Herman W, Kuo S, Martin C, Waltje A, Mihalcea R, Min D, Perez-Rosas V, Prosser L, Resnicow K, Ye W, Shao H, Zhang P, Luchsinger J, Sanchez D, Assuras S, Groessl E, Sakha F, Chong H, Hillery N, Abdouch I, Bahtiyar G, Brantley P, Broyles F, Canaris G, Copeland P, Craine J, Fein W, Gliwa A, Hope L, Lee M, Meiners R, Meiners V, O’Neal H, Park J, Sacerdote A, Sledge Jr E, Soni L, Steppel-Reznik J, Turchin A. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). Circulation 2024, 149: 993-1003. PMID: 38344820, PMCID: PMC10978227, DOI: 10.1161/circulationaha.123.066604.Peer-Reviewed Original ResearchConceptsType 2 diabetesGlucose-lowering medicationsCardiovascular diseaseMACE-4MACE-3Baseline prevalence of cardiovascular diseasesCardiovascular outcomesPrevalence of cardiovascular diseaseCohort of adultsContemporary cohort of adultsCox proportional hazards modelsEffects of glucose-lowering medicationsLow cardiovascular riskProportional hazards modelType 2 diabetes durationRisk of cardiovascular eventsPrespecified outcomesHazards modelCardiovascular riskInvestigated cardiovascular outcomesLow riskLiraglutide-treated groupStatistically significant differenceHeart failureCumulative incidence
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply